S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:ZSAN

Zosano Pharma Stock Forecast, Price & News

$0.62
+0.01 (+1.48 %)
(As of 12/4/2020 04:56 PM ET)
Add
Compare
Today's Range
$0.61
Now: $0.62▼
$0.64
50-Day Range
$0.34
MA: $0.50▼
$0.67
52-Week Range
$0.33
Now: $0.62▼
$1.96
Volume1.32 million shs
Average Volume3.91 million shs
Market Capitalization$42.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.98
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its intracutaneous microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Zosano Pharma logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.41 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZSAN
Previous Symbol
CUSIPN/A
CIK1587221
Webwww.zosanopharma.com
Phone510-745-1200
Employees56

Debt

Debt-to-Equity RatioN/A
Current Ratio0.68
Quick Ratio0.68

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.40 per share
Price / Book1.56

Profitability

EPS (Most Recent Fiscal Year)($2.29)
Net Income$-37,590,000.00
Net MarginsN/A
Return on Equity-227.55%
Return on Assets-79.80%

Miscellaneous

Outstanding Shares68,583,000
Market Cap$42.69 million
Next Earnings Date3/12/2021 (Estimated)
OptionableNot Optionable
$0.62
+0.01 (+1.48 %)
(As of 12/4/2020 04:56 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZSAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZSAN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions

How has Zosano Pharma's stock price been impacted by Coronavirus?

Zosano Pharma's stock was trading at $0.5662 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZSAN shares have increased by 10.2% and is now trading at $0.6240.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Zosano Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zosano Pharma or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Zosano Pharma?

Wall Street analysts have given Zosano Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zosano Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zosano Pharma's next earnings date?

Zosano Pharma is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Zosano Pharma.

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Co. (NASDAQ:ZSAN) released its quarterly earnings data on Wednesday, November, 18th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02.
View Zosano Pharma's earnings history.

When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?

Shares of Zosano Pharma reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for ZSAN?

3 brokers have issued twelve-month price targets for Zosano Pharma's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Zosano Pharma's share price to reach $2.00 in the next year. This suggests a possible upside of 220.5% from the stock's current price.
View analysts' price targets for Zosano Pharma.

Who are some of Zosano Pharma's key competitors?

Some companies that are related to Zosano Pharma include Spring Bank Pharmaceuticals (SBPH), Checkpoint Therapeutics (CKPT), Matinas BioPharma (MTNB), Taiwan Liposome (TLC), Ampio Pharmaceuticals (AMPE), Ritter Pharmaceuticals (RTTR), Biofrontera (BFRA), OncoSec Medical (ONCS), ContraFect (CFRX), Galectin Therapeutics (GALT), LifeVantage (LFVN), vTv Therapeutics (VTVT), Enlivex Therapeutics (ENLV), Aclaris Therapeutics (ACRS) and NuCana (NCNA).
View all competitors.

What other stocks do shareholders of Zosano Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Aeterna Zentaris (AEZS), Pennsylvania Real Estate Investment Trust (PEI), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Cannabics Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Hallador Energy (HNRG) and EnLink Midstream (ENLC).

Who are Zosano Pharma's key executives?

Zosano Pharma's management team includes the following people:
  • Mr. Steven Lo, Pres, CEO & Director (Age 53, Pay $155.67k)
  • Dr. Donald J. Kellerman, VP of Clinical Devel. & Medical Affairs (Age 65, Pay $353k)
  • Ms. Christine Matthews, Chief Financial Officer (Age 52)
  • Ms. Hayley Lewis, Sr. VP of Operations (Age 44)
  • Jeffrey L. Quillen, Sec.

When did Zosano Pharma IPO?

(ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

What is Zosano Pharma's stock symbol?

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Who are Zosano Pharma's major shareholders?

Zosano Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Stanley (1.85%), BlackRock Inc. (1.61%), Caas Capital Management LP (0.66%), AJ Wealth Strategies LLC (0.20%), WINTON GROUP Ltd (0.18%) and Squarepoint Ops LLC (0.04%).
View institutional ownership trends for Zosano Pharma.

Which institutional investors are buying Zosano Pharma stock?

ZSAN stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Caas Capital Management LP, AJ Wealth Strategies LLC, WINTON GROUP Ltd, and Squarepoint Ops LLC.
View insider buying and selling activity for Zosano Pharma.

How do I buy shares of Zosano Pharma?

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zosano Pharma's stock price today?

One share of ZSAN stock can currently be purchased for approximately $0.62.

How big of a company is Zosano Pharma?

Zosano Pharma has a market capitalization of $42.80 million. The biotechnology company earns $-37,590,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Zosano Pharma employs 56 workers across the globe.

What is Zosano Pharma's official website?

The official website for Zosano Pharma is www.zosanopharma.com.

How can I contact Zosano Pharma?

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.